225 related articles for article (PubMed ID: 34734169)
1. Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment.
Cowell JK; Hu T
Cancer Drug Resist; 2021; 4(3):607-619. PubMed ID: 34734169
[TBL] [Abstract][Full Text] [Related]
2. Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.
Cowell JK; Qin H; Hu T; Wu Q; Bhole A; Ren M
Int J Cancer; 2017 Nov; 141(9):1822-1829. PubMed ID: 28646488
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndrome.
Liu Y; Cai B; Chong Y; Zhang H; Kemp CA; Lu S; Chang CS; Ren M; Cowell JK; Hu T
Cell Death Dis; 2020 Oct; 11(10):884. PubMed ID: 33082322
[TBL] [Abstract][Full Text] [Related]
4. 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.
Guasch G; Ollendorff V; Borg JP; Birnbaum D; Pébusque MJ
Mol Cell Biol; 2001 Dec; 21(23):8129-42. PubMed ID: 11689702
[TBL] [Abstract][Full Text] [Related]
5. Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice.
Ren M; Qin H; Wu Q; Savage NM; George TI; Cowell JK
Int J Cancer; 2016 Aug; 139(4):836-40. PubMed ID: 27005999
[TBL] [Abstract][Full Text] [Related]
6. Myeloid neoplasms with eosinophilia.
Reiter A; Gotlib J
Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
[TBL] [Abstract][Full Text] [Related]
7. 8p11 myeloproliferative syndrome: a review.
Jackson CC; Medeiros LJ; Miranda RN
Hum Pathol; 2010 Apr; 41(4):461-76. PubMed ID: 20226962
[TBL] [Abstract][Full Text] [Related]
8. The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT.
Ryan MR; Sohl CD; Luo B; Anderson KS
Mol Cancer Res; 2019 Feb; 17(2):532-543. PubMed ID: 30257990
[TBL] [Abstract][Full Text] [Related]
9. Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.
Ren M; Cowell JK
Blood; 2011 Jun; 117(25):6837-47. PubMed ID: 21527531
[TBL] [Abstract][Full Text] [Related]
10. Myeloid/lymphoid neoplasm with
Chen D; Liu G; Lewis MR; Li X; Ulrickson M; Nath R; Chen W
Leuk Res Rep; 2023; 19():100370. PubMed ID: 37275466
[TBL] [Abstract][Full Text] [Related]
11. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
Pozdnyakova O; Orazi A; Kelemen K; King R; Reichard KK; Craig FE; Quintanilla-Martinez L; Rimsza L; George TI; Horny HP; Wang SA
Am J Clin Pathol; 2021 Feb; 155(2):160-178. PubMed ID: 33367495
[TBL] [Abstract][Full Text] [Related]
12. Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.
Ren M; Qin H; Ren R; Tidwell J; Cowell JK
Cancer Res; 2011 Dec; 71(23):7312-22. PubMed ID: 21937681
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of two rare BCR-FGFR1
Barnes EJ; Leonard J; Medeiros BC; Druker BJ; Tognon CE
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 31980503
[TBL] [Abstract][Full Text] [Related]
14. Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.
Montenegro-Garreaud X; Miranda RN; Reynolds A; Tang G; Wang SA; Yabe M; Wang W; Fang L; Bueso-Ramos CE; Lin P; Medeiros LJ; Lu X
Hum Pathol; 2017 Jul; 65():147-156. PubMed ID: 28551329
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of chromosome 8p11.2 translocations and correlation with myeloid and lymphoid neoplasms associated with FGFR1 abnormalities in a consecutive cohort from nine institutions in Japan.
Usuki K; Kameda T; Kawano N; Ito T; Hashimoto Y; Shide K; Kawano H; Sekine M; Toyama T; Iizuka H; Sato S; Takeuchi M; Ishizaki J; Maeda K; Nakai M; Yamashita K; Kubuki Y; Shimoda K
Int J Hematol; 2024 Mar; ():. PubMed ID: 38457113
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia associated with FGFR1 abnormalities.
Lee H; Kim M; Lim J; Kim Y; Han K; Cho BS; Kim HJ
Int J Hematol; 2013 Jun; 97(6):808-12. PubMed ID: 23609419
[TBL] [Abstract][Full Text] [Related]
17. Identification of four new translocations involving FGFR1 in myeloid disorders.
Sohal J; Chase A; Mould S; Corcoran M; Oscier D; Iqbal S; Parker S; Welborn J; Harris RI; Martinelli G; Montefusco V; Sinclair P; Wilkins BS; van den Berg H; Vanstraelen D; Goldman JM; Cross NC
Genes Chromosomes Cancer; 2001 Oct; 32(2):155-63. PubMed ID: 11550283
[TBL] [Abstract][Full Text] [Related]
18. Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study.
Liang D; Chen Q; Guo Y; Zhang T; Guo W
Drug Des Devel Ther; 2017; 11():451-461. PubMed ID: 28255231
[TBL] [Abstract][Full Text] [Related]
19. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
20. [FGFR1 and MOZ, two key genes involved in malignant hemopathies linked to rearrangements within the chromosomal region 8p11-12].
Pébusque MJ; Chaffanet M; Popovici C; Birnbaum D
Bull Cancer; 2000 Dec; 87(12):887-94. PubMed ID: 11174118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]